PRAME derived peptides and immunogenic compositions comprising these

1. An immunogenic pharmaceutical composition comprising (a) a peptide having a length of 27 to 35 amino acids and comprising at least 27 contiguous amino acids from the amino acid sequence of the human PRAME protein and (b) an immune-stimulating amount of a pharmaceutically acceptable adjuvant,

wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein,

wherein said HLA class I epitope is capable of activating a CD8+ CTL in a human cancer patient and/or in a healthy control and is represented by the amino acid sequence selected from the group consisting of:

amino acid sequence including amino acids at positions 100-108 of SEQ ID NO: 21;

amino acid sequence including amino acids at positions 113-122 of SEQ ID NO: 21;

amino acid sequence including amino acids at positions 142-151 of SEQ ID NO: 21;

amino acid sequence including amino acids at positions 190-198 of SEQ ID NO: 21;

amino acid sequence including amino acids at positions 258-267 of SEQ ID NO: 21;

amino acid sequence including amino acids at positions 371-380 of SEQ ID NO: 21; and

amino acid sequence including amino acids at positions 425-433 of SEQ ID NO: 21;

wherein said HLA class II epitope is capable of activating a CD45RO positive CD4+ Th cell and is represented by the amino acid sequence selected from the group consisting of:

amino acid sequence including amino acids at positions 98-124 of SEQ ID NO: 21;

amino acid sequence including amino acids at positions 116-142 of SEQ ID NO: 21;

amino acid sequence including amino acids at positions 133-159 of SEQ ID NO: 21;

amino acid sequence including amino acids at positions 181-207 of SEQ ID NO: 21;

amino acid sequence including amino acids at positions 194-220 of SEQ ID NO: 21;

amino acid sequence including amino acids at positions 234-255 of SEQ ID NO: 21;

amino acid sequence including amino acids at positions 247-273 of SEQ ID NO: 21;

amino acid sequence including amino acids at positions 353-379 of SEQ ID NO: 21; and

amino acid sequence including amino acids at positions 424-450 of SEQ ID NO: 21, and

wherein the contiguous amino acid sequence from the human PRAME protein is selected from the group consisting of: amino acid sequences SEQ ID NOs: 6, 7, 8, 9, 10, 11, 12, 16, and 18.

2. The immunogenic pharmaceutical composition according to claim 1 , wherein the length of the contiguous amino acid sequence is 30-35 amino acids.

3. The immunogenic pharmaceutical composition according to claim 1 , wherein the HLA class I epitope is an HLA-A2 epitope.

4. The immunogenic pharmaceutical composition according to claim 1 , wherein the peptide consists of a contiguous amino acid sequence from the human PRAME protein that is selected from the group consisting of amino acid sequences SEQ ID NOs: 6, 7, 8, 9, 10, 11, 12, 16, and 18.

5. The immunogenic pharmaceutical composition according to claim 1 , wherein said peptide is modified by addition at the N- and/or C-terminus, of one amino acid.

6. The immunogenic pharmaceutical composition according to claim 1 , comprising at least two different peptides as defined in claim 1 .

7. The immunogenic pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable adjuvant acts via a Toll-like receptor.

8. The immunogenic pharmaceutical composition according to claim 1 for the treatment or prevention of cancer.

9. The immunogenic pharmaceutical composition according to claim 1 , wherein the cancer is a cancer in which the human PRAME protein is overexpressed.

10. The immunogenic pharmaceutical composition according to claim 1 , wherein the cancer is selected from the group consisting of: melanoma, lymphoma, papillomas, breast or cervical carcinomas, acute and chronic leukemias, medulloblastoma, non-small cell lung carcinoma, head and neck cancer, renal carcinoma, pancreatic carcinoma, prostate cancer, small cell lung cancer, multiple myeloma, sarcomas and hematological malignancies like chronic myeloid leukemia and acute myeloid leukemia.

11. The immunogenic pharmaceutical composition according to claim 9 , wherein the cancer is selected from the group consisting of: melanoma, lymphoma, papillomas, breast or cervical carcinomas, acute and chronic leukemias, medulloblastoma, non-small cell lung carcinoma, head and neck cancer, renal carcinoma, pancreatic carcinoma, prostate cancer, small cell lung cancer, multiple myeloma, sarcomas and hematological malignancies like chronic myeloid leukemia and acute myeloid leukemia.

12. The immunogenic pharmaceutical composition according to claim 1 , wherein the length of the contiguous amino acid sequence is 33-35 amino acids.

13. The immunogenic pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable adjuvant is synthetic.

14. The immunogenic pharmaceutical composition according to claim 7 , wherein the pharmaceutically acceptable adjuvant is selected from the group consisting of: Gram positive bacterial glycolipids, fimbriae, outer membrane proteins, heatshock proteins, mycobacterial lipoarabinomannans, dsRNA, poly(I:C), Gram negative glycolipids, viral coat or envelope proteins, taxol or derivatives thereof, hyaluronan containing oligosaccharides or fibronectins, bacterial flagellae or flagellin, mycobacterial lipoproteins, group B Streptococcus heat labile soluble factor (GBS-F), Staphylococcus modulins, and imidazoquinolines.

15. The immunogenic pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable adjuvant is selected from the group consisting of: dsRNA, poly(I:C), unmethylated CpG DNA, IC31, IMSAVAC, and Montanide.

16. The immunogenic pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable adjuvant is physically linked to the peptide.

17. The immunogenic pharmaceutical composition according to claim 1 , further comprising at least one immune modulator.